MedPath

GILEAD SCIENCES SL

šŸ‡ŗšŸ‡øUnited States
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Phase 2
Withdrawn
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2013-08-05
Last Posted Date
2021-08-19
Lead Sponsor
Gilead Sciences
Registration Number
NCT01915472

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

Phase 3
Completed
Conditions
Hepatitis C
Interventions
First Posted Date
2013-07-29
Last Posted Date
2015-03-24
Lead Sponsor
Gilead Sciences
Target Recruit Count
153
Registration Number
NCT01910636

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Phase 2
Completed
Conditions
Hepatitis C
Interventions
Drug: SOF
Drug: VEL
First Posted Date
2013-07-29
Last Posted Date
2018-11-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
323
Registration Number
NCT01909804

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking TruvadaĀ® for HIV Pre-Exposure Prophylaxis (PrEP)

Completed
Conditions
HIV
First Posted Date
2013-07-24
Last Posted Date
2021-09-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
10577
Registration Number
NCT01906255
Locations
šŸ‡ŗšŸ‡ø

Gilead Sciences, Inc., Foster City, California, United States

A Prospective, Observational Study of Individuals Who Seroconvert While Taking TruvadaĀ® for Pre-Exposure Prophylaxis (PrEP)

Completed
Conditions
HIV
First Posted Date
2013-07-18
Last Posted Date
2020-07-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
172
Registration Number
NCT01902472
Locations
šŸ‡ŗšŸ‡ø

Gilead Sciences, Inc., Foster City, California, United States

Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Phase 3
Completed
Conditions
Hepatitis C
Interventions
Drug: SOF
First Posted Date
2013-07-11
Last Posted Date
2015-05-29
Lead Sponsor
Gilead Sciences
Target Recruit Count
127
Registration Number
NCT01896193
Locations
šŸ‡·šŸ‡ŗ

Institute of Nutrition of Academy of Sciences, Moscow, Russian Federation

šŸ‡·šŸ‡ŗ

Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases, Saint-Petersburg, Russian Federation

šŸ‡·šŸ‡ŗ

Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department, Moscow, Russian Federation

and more 13 locations

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Completed
Conditions
Limited Scleroderma
Diffuse Scleroderma
First Posted Date
2013-06-19
Last Posted Date
2014-04-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
29
Registration Number
NCT01881529
Locations
šŸ‡¦šŸ‡ŗ

St Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia

A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA

Completed
Conditions
Pre-exposure Prophylaxis for Prevention of HIV Infection
First Posted Date
2013-05-31
Last Posted Date
2018-03-27
Lead Sponsor
Gilead Sciences
Target Recruit Count
64186
Registration Number
NCT01865799
Locations
šŸ‡ŗšŸ‡ø

Gilead Sciences, Inc., Foster City, California, United States

A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication

Completed
Conditions
HIV Infection
First Posted Date
2013-05-31
Last Posted Date
2018-03-30
Lead Sponsor
Gilead Sciences
Target Recruit Count
99
Registration Number
NCT01865786
Locations
šŸ‡ŗšŸ‡ø

Antiretroviral Pregnancy Registry, Wilmington, North Carolina, United States

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Phase 2
Completed
Conditions
Hepatitis C
Interventions
Drug: SOF
Drug: VEL
First Posted Date
2013-05-21
Last Posted Date
2018-11-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
379
Registration Number
NCT01858766
Locations
šŸ‡ŗšŸ‡ø

VA Long Beach Healthcare System, Long Beach, California, United States

šŸ‡ŗšŸ‡ø

University of Florida Center for Clinical Trials Research, Gainesville, Florida, United States

šŸ‡ŗšŸ‡ø

ID Care, Hillsborough, New Jersey, United States

and more 48 locations
Ā© Copyright 2025. All Rights Reserved by MedPath